: The chemokine receptor CXCR4 has been identified as a co-receptor for the infection of cells by HIV and is thought to play a key role in the progression to AIDS. We have used a highly diverse, oriented peptide library approach to identify small peptide ligands for CXCR4. The goals of this research are to characterize the CXCR4 inhibitors identified so far, identify additional lead series, and carry out the optimization of the lead series with respect to antiviral potency and selectivity. The properties of the consensus-identified CXCR4-binding peptides will be characterized according to their signalling properties, their ability to inhibit gp120 binding, their cellular toxicity, their specificity for the CXCR4 receptor, and their ability to block HIV infection. The identification and clinical development of a peptide which blocks the binding of HIV to CXCR4 will result in an important new therapeutic class in the arsenal for use against AIDS.

Proposed Commercial Applications

NOT AVAILABLE

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
1R44AI050414-01
Application #
6405592
Study Section
Special Emphasis Panel (ZRG1-AARR (10))
Program Officer
Bridges, Sandra H
Project Start
2001-07-01
Project End
2002-01-31
Budget Start
2001-07-01
Budget End
2002-01-31
Support Year
1
Fiscal Year
2001
Total Cost
$98,528
Indirect Cost
Name
Consensus Pharmaceuticals, Inc.
Department
Type
DUNS #
City
Medford
State
MA
Country
United States
Zip Code
02155